Pharma Industry News
August 19th, 2009
A new study is looking back to ancient Chinese herbal medicine for contemporary treatment options. The Chinese herb in question referred to as “thunder god vine,” has been shown to minimize inflammation for rheumatoid arthritis patients.
August 19th, 2009
The U.S. FDA and Roche have informed healthcare practitioners that patients being treated with CellCept, have reported cases of Pure Red Cell Aplasia, also known as PRCA.
August 19th, 2009
Although, prGCD, a new drug used to treat patients with a unique genetic disorder - Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.
August 17th, 2009
University of Wisconsin-Madison researchers have published a report detailing their ability to block HIV infections in the lab, using synthetic proteins that prevent the virus from inhabiting healthy cells. The scientist’s synthetic molecules that hinder the HIV protein, gp41, from contacting host cell proteins.
August 17th, 2009
Novartis has recently announced the U.S. FDA approval of their multiple sclerosis treatment drug: Extavia (Interferon beta 1-b). The FDA approved the drug for patients that suffer from a relapse of the auto immune disease, or for those patients whom are newly diagnosed with MS.
August 17th, 2009
After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.
August 17th, 2009
The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.
August 13th, 2009
Specialty pharmaceutical company, who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical tria
August 13th, 2009
The U.S. FDA has recently announced two rules that are intended to explicate accessible strategies for critically ill patients who are interested in obtaining access to investigational drugs and biologics.
August 12th, 2009
Researchers from the University of California have released a study that claims a simulated form of a material found in the kudzu vine can minimize alcoholic drinking and help relapses
